A Randomized, Controlled Study of HIF-PH Inhibitors in patients with Heart Failure and Renal Anemia

Murohara Toyoaki0 个研究点目标入组 40 人开始时间: 2022年3月17日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1, Patients with symptoms of heart failure or a history of heart failure admission with renal anemia.
•2, Hb 11g/dL or less within one month.
•3, Prescribed standard heart failure drugs.
•4, NT pro BNP of 400 pg/mL or more in sinus rhythm or 900/pg mL or more in patients with atrial fibrillation within one month.
•5, Chronic renal failure

•1, Uncontrolled hypertension (systolic >160 mmHg or diastolic >100 mmHg)
•2, Predisposition to thrombosis and/or high risk of thrombosis
•3, History of thrombotic cerebral infarction or pulmonary embolism
•4, Pulmonary hypertension
•5, Bleeding complications within 12 weeks
•6, Treated cancer within 5 years or malignant tumors that require treatment
•7, Hepatic disorder (AST > 100IU/L or ALT > 100IU/L)
•8, Myocardial infarction, unstable angina pectoris, stroke, or transient ischemic attack within 12 weeks prior to obtaining consent.
•9, Patients who have undergone or are scheduled to undergo PCI, CABG, valvuloplasty, or valve replacement within 12 weeks prior to obtaining consent.
•10, Performed pacemaker implantation surgery within 12 weeks prior to obtaining consent, or are scheduled to undergo such surgery at the time of obtaining consent.
•11, Patients on maintenance hemodialysis or those who are likely to be on hemodialysis within one year.
•12, Lactating or pregnant.
•13, Proliferative diabetic retinopathy, macular edema, exudative age-related macular degeneration, retinal vein occlusion.
•14, Patients with a history of hypersensitivity to the HIF-Phi drug
•15, Patients using ESA and HIF-PH inhibitor within 12 weeks.
•16, Inappropriated cases

发起方

Murohara Toyoaki